Physician profile
Chad Summy
NPI 1679595854
$3,551.75
in general payments reported to CMS, 2019-2025
13 companies · $616 in 2025
The $616 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $120 · 2021: $53.83 · 2022: $153 · 2023: $139 · 2024: $2,188 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173 · Travel and Lodging: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,173.04 |
| Travel and Lodging | $770.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,724.25 | 2019-2025 | Prostep, Augment Injectable, Ortholoc 2 Lapifuse |
| Organogenesis INC. | $268.02 | 2022-2024 | Puraply Wound Matrix, Puraply |
| Smith+Nephew, INC. | $140.73 | 2020-2025 | Grafix Pl, Collagenase Santyl, Stravix Pl |
| Zimmer Biomet Holdings, INC. | $122.09 | 2019 | |
| Kerecis Limited | $64.94 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Conetic Solutions, INC. | $57.24 | 2020-2021 | |
| Horizon Therapeutics Plc | $47.72 | 2019-2021 | |
| Becton, Dickinson and Company | $32.27 | 2025 | Surgiphor |
| Grt US Holding, INC. | $29.36 | 2022 | |
| Paragon 28, INC. | $19.20 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $18.38 | 2024 | Exparel |
| Paratek Pharmaceuticals, INC. | $14.55 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Summy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.